Implantable Bio-Artificial Pancreas (iBAP)

项目摘要 大约300万美国人和全世界大约2400万人受到1型糖尿病的影响 (T1D)。胰岛素注射后的血糖监测，同种异体器官胰腺移植 同种异体胰岛移植是治疗T1D最常见的方法。这些治疗方法可以达到 对许多患者血糖控制，但会导致严重的并发症。生物人工胰腺是一种很有前途的 治疗T1D，因为它含有功能性胰岛。然而，之前试图开发一种生物人造 由于传质不足和贝塔细胞供应有限，该设备受到了严重限制。舒沃博士 Roy(PI)已经开发出硅纳米孔膜(SNM)来实现高效的血液超滤 同时选择性地为生物人工肾项目和该项目的成功保留特定的溶质 可直接移植到可植入的生物人工胰腺(IBAP)。超高透水性 SNM的特性将使适当的质量传输(特别是氧气、葡萄糖和胰岛素) 在达到最佳的β电池性能的同时，SNM的超选择性孔隙特性使 史无前例的免疫隔离。此外，IBAP还将利用从人类胚胎干细胞获得的全功能干细胞 为IBAP的发展和临床翻译提供和无限供应的β细胞。

Project Summary Approximately 3 million Americans and around 24 million people worldwide are affected by Type 1 Diabetes (T1D). Glucose monitoring followed by insulin injection, allogeneic whole organ pancreas transplantation, and allogeneic islet transplantation are the most common treatments for T1D. These treatments can achieve glycemic control for many patients but result in serious complications. A bioartificial pancreas is a promising treatment for T1D because it contains functional islets. However, previous attempts to develop a bioartificial device have been severely limited by insufficient mass transfer and a limited supply of beta cells. Dr. Shuvo Roy (PI) has developed silicon nanopore membranes (SNM) to achieve high-efficiency blood ultrafiltration while selectively retaining specific solutes for the Bioartificial Kidney project and this project's successes are directly transferrable to the implantable bioartificial pancreas (the iBAP). The ultra-high hydraulic permeability characteristic of the SNM will enable appropriate mass transport (especially oxygen, glucose, and insulin) within to achieve optimal beta cell performance, while the ultra-selective pore characteristic of the SNM enable unprecedented immunoisolation. Also the iBAP will utilize a human embryonic stem cell derived fully functional beta cell that provides and unlimited supply of beta cells for iBAP development and clinical translation.